Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
NCT ID: NCT00055146
Last Updated: 2009-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
41 participants
INTERVENTIONAL
2003-03-31
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
NCT00082940
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
NCT00117845
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
NCT00493129
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
NCT01515176
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
NCT01361711
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ONTAK
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have received at least one prior purine analogue-based chemotherapy regimen.
* ECOG Performance Status of 0, 1, or 2.
* Female patients cannot be pregnant and must use birth control during the course of the study and for three weeks after the study ends.
Exclusion Criteria
* Received any therapy for CLL within 35 days prior to study entry.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elyane Lombardy, M.D.
Role: STUDY_DIRECTOR
Ligand Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pacific Coast Hematology/Oncology Medical Group, Inc.
Fountain Valley, California, United States
UCSD School of Medicine
La Jolla, California, United States
Rush-Presbyterian St. Luke's Cancer Center
Chicago, Illinois, United States
Weill Medical College of Cornell University/New York Presbyterian Hospital
New York, New York, United States
University of Texas, M.D. Anderson Cancer Center
Houston, Texas, United States
Montecaseros
Mendoza, , Argentina
Peter MacCallum Cancer Institute
East Melbourne, Victoria, Australia
Oncology Day Unit, Frankston Hospital
Frankston, , Australia
Hospital Araujo Jorge - Associacao de Combate ao Cancer em Goias
Goiânia, Goiás, Brazil
Hospital de Clinicas da Universidade Federal do Parana
Curitiba, Paraná, Brazil
Universidade Federal do Rio de Janeiro - Hospital Universitario Clementino Fraga Filho
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital de Cancer de Barretos - Fundacao Pio XII
Barretos, São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, São Paulo, Brazil
Sir Mortimer B. Davis - Jewish General Hospital
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
L4389-34
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.